Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP7214 plus Azacitidine in AML, MDS, and CMML
NCT05246384Phase 2Withdrawn
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of RP7214 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Maximum Tolerated Dose / Recommended Phase 2 Dose at 28 days. Planned start Jan 2023; status: withdrawn.
02
Drugs
RP7214
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05246384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246384.